UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000023976
Receipt No. R000027599
Scientific Title Plasma biomarker reflecting cerebral amyloid deposition: a multicenter study for the clinical application
Date of disclosure of the study information 2016/10/01
Last modified on 2017/07/09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Plasma biomarker reflecting cerebral amyloid deposition: a multicenter study for the clinical application
Acronym Plasma biomarker for Alzheimer's disease
Scientific Title Plasma biomarker reflecting cerebral amyloid deposition: a multicenter study for the clinical application
Scientific Title:Acronym Plasma biomarker for Alzheimer's disease
Region
Japan

Condition
Condition Alzheimer's disease
Other Dementia
Mild cognitive impairment (MCI)
Healthy volunteer
Classification by specialty
Neurology Geriatrics Psychiatry
Radiology Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 We have recently developed a novel plasma biomarker capable of highly sensitive detection of brain amyloid deposition (Kaneko et al., Proc Jpn Acad Ser B Phys Biol Sci, 2014). The objective of this study is to validate it's usefulness and plausibility for the clinical application by a multicenter study.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase II,III

Assessment
Primary outcomes The primary endpoint of the study is to evaluate the ability of our plasma biomarkers to estimate the presence (or absence) of brain amyloid deposition, by referring the results of amyloid-PET imaging as the gold standard.
Key secondary outcomes 1) To test quantitative correlation between plasma biomarker values and brain amyloid deposition.
2) To evaluate the performances (e.g. sensitivity and specificity) of the biomarkers for each clinical category
3) Longitudinal changes between the changes in clinical symptoms and biomarker values.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
50 years-old <=
Age-upper limit
100 years-old >=
Gender Male and Female
Key inclusion criteria 1) Alzheimer's disease (AD)
2) non-AD dementia
3) Mild cognitive impairment (MCI)
4) Healthy volunteer

Having no significant disease and good state of the body condition.
Key exclusion criteria Having a risk for the MRI measurements, such as a heart pacemaker, implanted body metals, and a nerve stimulator.
Having significant disease.
A history of alcohol or drug addiction.
Target sample size 400

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Akinori Nakamura
Organization National Center for Geriatrics and Gerontology
Division name Department of Clinical and Experimental Neuroimaging
Zip code
Address 7-430, Morioka, Obu, Aichi, Japan
TEL 0562-46-2311
Email nakamura@ncgg.go.jp

Public contact
Name of contact person
1st name
Middle name
Last name Akinori Nakamura
Organization National Center for Geriatrics and Gerontology
Division name Department of Clinical and Experimental Neuroimaging
Zip code
Address 7-430, Morioka, Obu, Aichi, Japan
TEL 0562-46-2311
Homepage URL
Email nakamura@ncgg.go.jp

Sponsor
Institute National Center for Geriatrics and Gerontology
Institute
Department

Funding Source
Organization The Japan Agency for Medical Research and Development (AMED)
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor The Tokyo Metropolitan Institute of Gerontology
Kindai University Hospital
Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 国立長寿医療研究センター(愛知県)
東京都健康長寿医療センター研究所(東京都)
近畿大学医学部附属病院 早期認知症センター(大阪府)

Other administrative information
Date of disclosure of the study information
2016 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2016 Year 09 Month 07 Day
Date of IRB
Anticipated trial start date
2016 Year 10 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information This is a multicenter study in Japan. The study design is mainly prospective, but it also analyze available retrospective data sets.

Management information
Registered date
2016 Year 09 Month 08 Day
Last modified on
2017 Year 07 Month 09 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027599

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.